Sphingosine 1-phosphate (S1P) induces COX-2 expression and PGE2 formation via S1P receptor 2 in renal mesangial cells. 2014

Anja Völzke, and Alexander Koch, and Dagmar Meyer Zu Heringdorf, and Andrea Huwiler, and Josef Pfeilschifter
Pharmazentrum Frankfurt/ZAFES, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany. Electronic address: voelzke@med.uni-frankfurt.de.

Understanding the mechanisms of sphingosine 1-phosphate (S1P)-induced cyclooxygenase (COX)-2 expression and prostaglandin E2 (PGE2) formation in renal mesangial cells may provide potential therapeutic targets to treat inflammatory glomerular diseases. Thus, we evaluated the S1P-dependent signaling mechanisms which are responsible for enhanced COX-2 expression and PGE2 formation in rat mesangial cells under basal conditions. Furthermore, we investigated whether these mechanisms are operative in the presence of angiotensin II (Ang II) and of the pro-inflammatory cytokine interleukin-1β (IL-1β). Treatment of rat and human mesangial cells with S1P led to concentration-dependent enhanced expression of COX-2. Pharmacological and molecular biology approaches revealed that the S1P-dependent increase of COX-2 mRNA and protein expression was mediated via activation of S1P receptor 2 (S1P2). Further, inhibition of Gi and p42/p44 MAPK signaling, both downstream of S1P2, abolished the S1P-induced COX-2 expression. In addition, S1P/S1P2-dependent upregulation of COX-2 led to significantly elevated PGE2 levels, which were further potentiated in the presence of Ang II and IL-1β. A functional consequence downstream of S1P/S1P2 signaling is mesangial cell migration that is stimulated by S1P. Interestingly, inhibition of COX-2 by celecoxib and SC-236 completely abolished the migratory response. Overall, our results demonstrate that extracellular S1P induces COX-2 expression via activation of S1P2 and subsequent Gi and p42/p44 MAPK-dependent signaling in renal mesangial cells leading to enhanced PGE2 formation and cell migration that essentially requires COX-2. Thus, targeting S1P/S1P2 signaling pathways might be a novel strategy to treat renal inflammatory diseases.

UI MeSH Term Description Entries
D008246 Lysophospholipids Derivatives of PHOSPHATIDIC ACIDS that lack one of its fatty acyl chains due to its hydrolytic removal. Lysophosphatidic Acids,Lysophospholipid,Acids, Lysophosphatidic
D008297 Male Males
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068579 Celecoxib A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN. 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide,Celebrex,SC 58635,SC-58635,SC58635
D000081025 Sphingosine-1-Phosphate Receptors A subfamily of lysophospholipid receptors with specificity for sphingosine-1-phosphate (e.g., FINGOLIMOD), sphinganine 1-phosphate, 4-hydroxysphinganine 1-phosphate. Sphingosine-1-Phosphate Receptor 1,Sphingosine-1-Phosphate Receptor 2,Sphingosine-1-Phosphate Receptor 3,Sphingosine-1-Phosphate Receptor 4,Sphingosine-1-Phosphate Receptor 5,AGR16 Protein,EDG5 Protein,Edg Receptors,Edg-5 Receptor,G-Protein Coupled Receptor H218,H218 Protein,Nrg-1 Receptor,Receptor, Sphingosine-1-Phosphate,S1P Receptor,S1P1 Receptor,S1P2 Receptor,S1P3 Receptor,S1P4 Receptor,S1P5 Receptor,Sphingosine 1-Phosphate Receptor,Sphingosine-1-Phosphate Receptor,Edg 5 Receptor,G Protein Coupled Receptor H218,Nrg 1 Receptor,Sphingosine 1 Phosphate Receptor,Sphingosine 1 Phosphate Receptor 1,Sphingosine 1 Phosphate Receptor 2,Sphingosine 1 Phosphate Receptor 3,Sphingosine 1 Phosphate Receptor 4,Sphingosine 1 Phosphate Receptor 5,Sphingosine 1 Phosphate Receptors
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013110 Sphingosine An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed) 4-Sphingenine,4 Sphingenine

Related Publications

Anja Völzke, and Alexander Koch, and Dagmar Meyer Zu Heringdorf, and Andrea Huwiler, and Josef Pfeilschifter
June 2016, Cellular signalling,
Anja Völzke, and Alexander Koch, and Dagmar Meyer Zu Heringdorf, and Andrea Huwiler, and Josef Pfeilschifter
January 2018, PloS one,
Anja Völzke, and Alexander Koch, and Dagmar Meyer Zu Heringdorf, and Andrea Huwiler, and Josef Pfeilschifter
March 2015, Journal of cellular physiology,
Anja Völzke, and Alexander Koch, and Dagmar Meyer Zu Heringdorf, and Andrea Huwiler, and Josef Pfeilschifter
October 2014, Journal of leukocyte biology,
Anja Völzke, and Alexander Koch, and Dagmar Meyer Zu Heringdorf, and Andrea Huwiler, and Josef Pfeilschifter
June 2006, Journal of cellular physiology,
Anja Völzke, and Alexander Koch, and Dagmar Meyer Zu Heringdorf, and Andrea Huwiler, and Josef Pfeilschifter
September 2017, Oncotarget,
Anja Völzke, and Alexander Koch, and Dagmar Meyer Zu Heringdorf, and Andrea Huwiler, and Josef Pfeilschifter
February 2011, Neurology,
Anja Völzke, and Alexander Koch, and Dagmar Meyer Zu Heringdorf, and Andrea Huwiler, and Josef Pfeilschifter
October 2010, European journal of cell biology,
Anja Völzke, and Alexander Koch, and Dagmar Meyer Zu Heringdorf, and Andrea Huwiler, and Josef Pfeilschifter
September 2006, Kidney international,
Anja Völzke, and Alexander Koch, and Dagmar Meyer Zu Heringdorf, and Andrea Huwiler, and Josef Pfeilschifter
July 2003, Cellular signalling,
Copied contents to your clipboard!